Medplus Health Services Ltd (MEDPLUS) — shareholding pattern, promoter holding, financials and share price
About Medplus Health Services Ltd (MEDPLUS)
Medplus Health Services Ltd operates in the Pharmacy Retail industry, within the Consumer Services sector. It trades on the NSE as MEDPLUS and on the BSE under scrip code 543427. Its ISIN is INE804L01022.
MedPlus Health Services Limited is primarily engaged in pharmaceuticals and diagnostic services across India. It operates a vast network of over 5,000 stores, making it the second-largest pharma retailer in the country.
The company added 500 stores in the past year, indicating its focus on scaling up operations and increasing market penetration. Its cluster-based expansion strategy emphasizes deepening reach in existing markets.
Listed peers in Pharmacy Retail: Aditya Birla Lifestyle Brands Ltd, Indiamart Intermesh Ltd, Brainbees Solutions Ltd, Vedant Fashions Ltd, Aditya Vision Ltd, V2 Retail Ltd.
Valuation & Returns
10 Jul 2026At ₹825.9 a share on 10 Jul 2026, Medplus Health Services Ltd (MEDPLUS) was valued at a price-to-earnings ratio of 45.18x against an industry P/E of 78.58x and a price-to-book of 5.7x on a book value of ₹144.88 per share as of Mar 2025. Solomo computes return on equity of 12.62% and return on capital employed of 13.84% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 45.18x
- Industry P/E
- 78.58x
- P/B
- 5.7x
- EPS (TTM)
- ₹18.28
- Book value / share
- ₹144.88
- ROE
- 12.62%
- ROCE
- 13.84%
- ROA
- 6.54%
- Debt / equity
- 0.64x
- Dividend yield
- 0%
- EBITDA margin
- 9.85%
- 52-week range
- ₹731.95 – ₹1,020.35
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medplus Health Services Ltd (MEDPLUS) reported revenue of ₹6,892 crore, net profit of ₹220 crore and earnings per share of ₹18.3. That compares with revenue of ₹6,136 crore and net profit of ₹150 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,864 crore and net profit ₹64 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,779 | 4,558 | 5,625 | 6,136 | 6,892 |
| Net profit (₹ cr) | 95 | 50 | 66 | 150 | 220 |
| EPS (₹) | 8.03 | 4.17 | 5.48 | 12.56 | 18.3 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 89.68% | 138.41% | 69.78% | 9.13% |
| Profit growth | - | - | 93.36% | 129.08% |
| Stock price CAGR | - | - | -3% | -13% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.19% of Medplus Health Services Ltd (MEDPLUS) (down 0.03 pp QoQ), foreign institutional investors (FII) hold 14.38% and domestic institutional investors (DII) hold 29.95%. Promoters have pledged 60.7% of their holding. Market capitalisation was ₹9,922 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2021.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA 7.32%, ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTIC 4.93%, FRANKLIN INDIA FLEXI CAP FUND 3.9%, SBI ELSS TAX SAVER FUND 3.39%, KOTAK SMALL CAP FUND 3.31%, FIDELITY FUNDS - INDIA FOCUS FUND 1.68%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.19% | 60.7% | 14.38% | 29.95% | 59.77% |
| Mar 2026 | 40.22% | 60.7% | 15.53% | 27.82% | 59.74% |
| Dec 2025 | 40.29% | 60.7% | 16.83% | 26.57% | 59.66% |
| Sep 2025 | 40.29% | 59.3% | 16.54% | 26.52% | 59.66% |
| Jun 2025 | 40.32% | 59.3% | 16.42% | 26.04% | 59.63% |
| Mar 2025 | 40.34% | 59.3% | 15.61% | 26.19% | 59.62% |
| Dec 2024 | 40.39% | 55.2% | 15.23% | 25.65% | 59.57% |
| Sep 2024 | 40.39% | 54.2% | 14.72% | 27.97% | 59.55% |